All-In Podcast: Inside the GLP-1 Gold Rush

Episode Summary
Date: September 29, 2025
Guest: Dave Ricks, CEO of Eli Lilly
Hosts: Chamath Palihapitiya, Jason Calacanis, David Sacks, David Friedberg

Main Theme

This episode dives deep into the meteoric rise of GLP-1 drugs for weight loss and metabolic health, featuring an in-depth interview with Eli Lilly CEO Dave Ricks. The hosts and Ricks explore the origins and impact of GLP-1s, Eli Lilly's business and innovation strategy, pricing and access issues, the implications for mental health and addiction, the challenge of the gray market and IP, the future of research funding, and larger questions about the American health care ecosystem.

Key Discussion Points and Insights

1. The Journey and Bet on GLP-1 Drugs

Timestamps: 00:04–05:08

• Market Impact: Eli Lilly’s market cap has soared, with a 1000% increase in stock since Ricks became CEO (Dave Ricks at 00:04).
• Origins of GLP-1s: The journey began in 2006 with the first GLP-1 drug as a twice-daily injection for diabetes. Early users reported weight loss as a side effect, seeding future innovation (Dave Ricks at 02:22).
• Breakthrough & Scale: In 2014, Eli Lilly scientists combined GLP-1 with another gut peptide, creating tirzepatide (now Manjaro). Phase 1 trials in Singapore were halted early due to “too much weight loss.” This set off massive investment in scaling supply chains and clinical studies (Dave Ricks at 03:35).
• Results: Manjaro achieved $8.1B in Q2 2025 revenue, making it the best-selling drug ever (Dave Ricks at 03:26).

"We had to stop the study because they were losing too much weight too quickly... From there it was just execution. We knew it was gonna be huge." – Dave Ricks (04:00)

2. Prices, Profits & Moral Imperative

Timestamps: 05:08–09:07

• Cost Dilemma: The high price ($1,000 initially, now down to $499, with ongoing reductions promised) creates both access issues and a wildly profitable business (Dave Ricks at 07:54).
• Host Challenges: Jason and Chamath press Ricks on the moral tension: “Isn’t it a moral imperative to bring this down 50% in price?” (Jason Calacanis at 07:19).
• R&D Funding Justification: Ricks emphasizes balancing price reductions with the need to fund innovation, noting a $14.2B R&D spend (25% of sales) this year.

"If we cut the price to say $100, there will be no more new medicines in this category because we'll have snuffed out essentially the incentive to create...[we] spent 25% of sales on R&D." – Dave Ricks (08:43)

3. GLP-1 Gray Market and IP Challenges

Timestamps: 05:17–06:04; 12:34–15:33

• Gray Market: An active, mostly Chinese-led gray market is emerging with peptide synthesis and copycat drugs, partially driven by lack of insurance coverage in the U.S. (Dave Ricks at 05:38).
• China and Patent Dynamics: China’s rapid, state-subsidized innovation, coupled with aggressive patent “hacking,” is driving global competition and depressing biotech valuations (Dave Ricks at 14:22).

"China's getting very good at patent hacking...they work backwards, sometimes driven by AI algorithms, to define chemical structures that will behave similarly but are outside the patent scope." – Dave Ricks (14:22)

4. Personal Stories & Societal Impact

Timestamps: 01:01–07:02; 16:41–18:33

• Jason’s Weight Loss Story: Jason credits Eli Lilly’s drugs with helping him lose over 40 pounds and dramatically improve his health and outlook, echoing the transformation for millions (Jason Calacanis at 01:01).
• Food Noise & Reset: Drugs act as a “reset,” reducing compulsive eating, with potential life-changing effects (Jason Calacanis at 07:02).
• Broad Pleiotropic Effects: Beyond weight loss, these drugs may aid metabolic health, addiction, mental health, and, in the future, longevity (Dave Ricks at 16:41).

5. Capital Allocation Strategy

Timestamps: 09:07–12:23

• Choices for Surplus: Ricks outlines Lilly’s approach toward organic R&D expansion, huge investment in U.S. manufacturing (six new plants; more to come), and strategic M&A, rather than just returning profits to shareholders.
• Human Capital: “We currently have about 4,200 PhD scientists at Lilly...about the same as MIT and Harvard combined.” (Dave Ricks at 10:27)

6. Biotech Funding Crisis

Timestamps: 12:34–14:13

• VC Pullback: Funding for biotech startups has dropped dramatically as investors chase faster returns in AI and tech; many public biotechs trade below cash value (Dave Ricks at 13:07).
• Crowded IPO Market & China’s Role: Excess biotech IPOs and China’s subsidized swarm model add pressure.

7. Lifestyle, Biohacking, and the Future of Preventive Medicine

Timestamps: 15:33–18:33

• Dave Ricks’ Routine: Focus on sleep, plant-heavy diet, movement, social relationships – not extreme biohacking. He has not (yet) used GLP-1s himself (“yet”).
• Pharma vs. Biohackers: Eli Lilly focuses on rigorously proven disease interventions, not the general “wellness” approach of biohackers, though they observe trends in real time (Dave Ricks at 17:47).
• Forward-Looking: Ricks sees a future where low-dose use of GLP-1s in people over 60 could boost general longevity.

"Over time, I think we're going to get to a point where taking pretty low doses for most people, say over 60, 58, is not a terrible idea and it may help you live longer." – Dave Ricks (17:10)

8. GLP-1s, Mental Health, and Addiction

Timestamps: 18:33–20:13

• Unexpected Effects: Clinical trials show that GLP-1 drugs reduce smoking, gambling, compulsive shopping, and possibly symptoms of mental health disorders like bipolar and major depression.
• New Therapeutics: Eli Lilly is developing GLP-1 variants with stronger neuropsychiatric benefits, targeting depression and bipolar disorder (Dave Ricks at 19:35).

"When we started doing these studies at scale, it was immediately obvious people stopped smoking. Like—a lot of people stopped smoking." – Dave Ricks (19:01)

9. Food System, Health Policy, and the Spread of Obesity

Timestamps: 20:13–21:50

• Root Cause: The American processed food system is a major driver of obesity and metabolic ill health ("We are the least healthy metabolic big country... it's the food we feed ourselves." – Dave Ricks at 20:26).
• Diet Dogma: The anti-fat, high-carb dogma (“carb thing”) of recent decades contributed heavily to today’s crisis.

10. Drug Advertising, Media, and Public Trust

Timestamps: 21:50–23:57

• Advertising Controversy: Drug companies like Lilly spend heavily on consumer advertising; Ricks is candid, saying he’d prefer less advertising and more R&D, but regulation and competitive pressure lock everyone in (“mutually assured destruction”).
• Media Conflicts: Hosts raise questions about the influence pharma ad dollars have on mainstream media coverage.

"I'd be for a system where we don't have nearly as much drug advertising, to be clear. The ads annoy people. They're poorly constructed, owing to regulation built for magazine print advertisements." – Dave Ricks (22:25)

11. AI, ChatGPT, and Patient Empowerment

Timestamps: 24:10–25:22

• Rise of LLMs in Health Research: Ricks praises the democratization of medical knowledge via AI tools, saying, “I think it's a huge plus. I do it myself…I also do it just to see what the different models are producing about our drugs” (24:26).
• Consumer Info: Patients can now arrive better informed than their doctors, changing the information dynamic in health care.

12. Public Research Funding & University Role

Timestamps: 25:22–28:02

• NIH Budget Issues: Ricks acknowledges the historic value of NIH-funded research, but questions how grant money is allocated and whether universities are always the best stewards.
• Need for Sunshine: He calls for more transparency and competitiveness in public research funding.

13. PBMs (Pharmacy Benefit Managers) & System Reform

Timestamps: 28:02–29:28

• Declining Value: Ricks suggests PBMs have outlived their original usefulness—“probably we're at the end of that S curve cycle and should get to something else” (28:21).
• Systemic Bloat: Consolidation means PBMs now prioritize their own profit over patients’, adding complexity and opacity to drug pricing for little actual benefit.

14. What’s Next? Future of Breakthrough Rx

Timestamps: 29:28–30:20

• Next Big Thing: Ricks bets the next blockbuster therapeutics will be in brain diseases: depression, dementia, autism—areas of massive unmet need and suffering.

"Part of what we try to do is allocate capital into spaces where there are no drugs, hoping to hit the dartboard... That's how we got obesity drugs." – Dave Ricks (29:29)

Notable Quotes & Memorable Moments

• "Together, we've lost a Friedberg." – Jason Calacanis on his and Sacks’ weight loss (01:23)
• "Drug development is hard and long and requires a fair amount of failure and discipline, a huge amount of capital." – Dave Ricks (02:22)
• "Once I cycled off it for months and am now on an extremely low dose, the food noise and my discipline has come back. There's something about a certain moment where you get too far over it..." – Jason Calacanis (06:04)
• "I'm all for skepticism of science. That's what scientific process is... But if we restrict access while we're asking these questions, I worry." – Dave Ricks (21:20)
• "If you look at human suffering globally, 40% is brain disease...and what we've had so far has not worked." – Dave Ricks (29:29)
• "Do you supplement? ... Is there anything?" – David Friedberg, teasing out Ricks’ health habits (15:51)

Timestamps for Key Segments

| Timestamp | Topic | |-----------|--------------------------------------------------------------| | 00:04 | Origins and meteoric rise of Eli Lilly and GLP-1 | | 01:01 | Jason Calacanis’ personal weight loss experience | | 03:26 | Manjaro’s record-breaking global sales | | 05:38 | The GLP-1 gray market and global copycat problem | | 07:19 | Price, profits, and the question of affordable access | | 09:07 | Capital allocation: R&D, CapEx, and buybacks | | 12:34 | The biotech funding crisis and China’s strategic competition | | 14:22 | Patent law and Chinese “patent hacking” | | 16:41 | Use of GLP-1s for longevity, biohacking trends | | 18:33 | GLP-1s for addiction, mental health, and new drug horizons | | 20:13 | American health crisis and the food system | | 21:50 | Role and impact of drug advertising in media | | 24:10 | AI, ChatGPT, and patient empowerment | | 25:22 | The future of public research funding and universities | | 28:02 | The PBM system and potential reforms | | 29:28 | The next big pharma breakthrough: Brain diseases |

Conclusion

This episode provides an unfiltered look at the business, science, and ethics of pharma’s new frontier—from unprecedented medical breakthroughs to moral and systemic healthcare questions. Dave Ricks is candid about the trade-offs between profit, innovation, and access. The discussion weaves personal stories, public health strategy, and industry disruption into one of the most pressing conversations of the decade.